Attovia Therapeutics stock heads into October 8 data presentations
Published on 10/05/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Attovia Therapeutics stock last traded at USD 17.17 on Nasdaq on October 2, 2026, down 3.49 percent from the prior session. The clinical-stage biotechnology company is now approaching a scheduled data presentation that could give investors a new read on its lead programs.
According to Attovia on September 28, 2026, the company will present four posters at the Fall Clinical Dermatology Conference in Las Vegas from October 8, 2026, through October 11, 2026. Three posters concern ATTO-1310, while one covers preclinical data for ATTO-2306.
ATTO-1310 supplies the catalyst
The planned ATTO-1310 material includes interim Phase 1b data in patients with high-itch atopic dermatitis or chronic pruritus. The company also plans presentations on Phase 1a safety, pharmacokinetics and pharmacodynamics data from healthy adults, giving the program several clinical angles rather than a single efficacy update.
The October 8 event follows the European Academy of Dermatology and Venereology Congress, where Attovia listed two ATTO-1310 posters and one additional research presentation. The sequence puts early clinical evidence at the center of the stock story, while ATTO-2306 remains at the preclinical stage, according to Attovia.
Analyst target contrasts with losses
According to MarketBeat on October 4, 2026, six analysts carry a Moderate Buy consensus, with five buy ratings and one hold rating. The average 12-month price target is USD 42.20, which lies 145.72 percent above the USD 17.17 last price; individual targets listed in the report span USD 30.00 to USD 52.00.
The financial profile remains that of a development-stage biotech. Attovia reported USD 0.45 million in collaboration revenue and a USD 4.88 loss per share for the quarter, according to MarketBeat. The absence of a commercial product portfolio keeps clinical data and financing capacity central to the valuation discussion.
Stock remains below yearly high
ATTO was last at USD 17.17 on Nasdaq on October 2, 2026, with a 52-week range of USD 16.15 to USD 28.00 and market capitalization of USD 738.8 million. The last price stood 38.68 percent below the yearly high, leaving the October data presentations as the next dated operating checkpoint.
Attovia Therapeutics stock details
- Company: Attovia Therapeutics, Inc.
- Ticker: ATTO
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 17.17
- Market capitalization: USD 738.8 million (as of October 2, 2026)
- 52-week range: USD 16.15-28.00 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
Upcoming dates for Attovia Therapeutics stock
- October 8, 2026: Fall Clinical Dermatology Conference presentations begin
